| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Myeloproliferative Disorders |
U.O. Ematologia, Ospedali Riuniti, Bergamo, Italy
Correspondence: Guido Finazzi, U.O. Ematologia, Ospedali Riuniti, Largo Barozzi 1 24128 Bergamo, Italy. Phone: international +035.269493; Fax: international +035.266147. E-mail: gfinazzi{at}ospedaliriuniti.bergamo.it
We compared the laboratory and clinical findings of 179 patients with essential thrombocythemia (ET) and 77 with polycythemia vera (PV) classified according to the presence of the JAK2 V617F mutation. A gradient between patients with JAK2 wild-type ET, JAK2 V617F ET and PV (all carrying the JAK2 mutation) was observed. The rate of thrombotic complications in JAK2-positive ET was significantly higher than in wild-type ET and not statistically different from that of PV patients.
Key words: thrombosis, essential thrombocythemia, polycythemia vera, JAK2 mutation.
This article has been cited by other articles:
|
|
 |
|
  S. Sozer, M. I. Fiel, T. Schiano, M. Xu, J. Mascarenhas, and R. Hoffman The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome Blood, May 21, 2009; 113(21): 5246 - 5249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Florena, C Tripodo, A Di Bernardo, E Iannitto, C Guarnotta, R Porcasi, S Ingrao, V Abbadessa, and V Franco Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis J. Clin. Pathol., April 1, 2009; 62(4): 331 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marchetti, E. Castoldi, H. M. H. Spronk, R. van Oerle, D. Balducci, T. Barbui, J. Rosing, H. ten Cate, and A. Falanga Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera Blood, November 15, 2008; 112(10): 4061 - 4068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Beer, P. J. Campbell, L. M. Scott, A. J. Bench, W. N. Erber, D. Bareford, B. S. Wilkins, J. T. Reilly, H. C. Hasselbalch, R. Bowman, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort Blood, July 1, 2008; 112(1): 141 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. De Stefano, T. Za, E. Rossi, A. M. Vannucchi, M. Ruggeri, E. Elli, C. Mico, A. Tieghi, R. R. Cacciola, C. Santoro, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments Haematologica, March 1, 2008; 93(3): 372 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi, G. Longo, V. Ponziani, L. Tozzi, L. Pieri, V. Santini, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia Haematologica, January 1, 2008; 93(1): 41 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, R. M. Marfisi, G. Finazzi, V. Guerini, F. Fabris, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia Blood, August 1, 2007; 110(3): 840 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Skoda The Genetic Basis of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Vannucchi and T. Barbui Thrombocytosis and Thrombosis Hematology, January 1, 2007; 2007(1): 363 - 370. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
